Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3810477 in Healthy Volunteers
NCT06984926Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI3810477 (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-Emergent Adverse Events. Started Jun 2025; status: completed.
02
Drugs
BI3810477
Beyond the preview
Go deeper on NCT06984926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984926.